[
  {
    "ts": null,
    "headline": "Hartford Equity Income Fund Q4 2024 Commentary",
    "summary": "Hartford Equity Income Fund (I share) underperformed the Russell 1000 Value Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=f95c07e653005714d4816a7784c66ad729b2d2ab7264888ba8a672949ffd2bed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740435780,
      "headline": "Hartford Equity Income Fund Q4 2024 Commentary",
      "id": 132867316,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2095584352/image_2095584352.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Hartford Equity Income Fund (I share) underperformed the Russell 1000 Value Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=f95c07e653005714d4816a7784c66ad729b2d2ab7264888ba8a672949ffd2bed"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Dividend And Growth Fund Q4 2024 Commentary",
    "summary": "Hartford Dividend and Growth Fund (I shares) underperformed the S&P 500 Index for the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=7dc980509a36eac275b2142e4fca0e11820c26f6d268f82362164c22c1478a84",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740405780,
      "headline": "Hartford Dividend And Growth Fund Q4 2024 Commentary",
      "id": 132865261,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2095584352/image_2095584352.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Hartford Dividend and Growth Fund (I shares) underperformed the S&P 500 Index for the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=7dc980509a36eac275b2142e4fca0e11820c26f6d268f82362164c22c1478a84"
    }
  },
  {
    "ts": null,
    "headline": "European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention",
    "summary": "– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –– Both Applications Will Be Assessed in...",
    "url": "https://finnhub.io/api/news?id=aacf2aeb8946b8845ed4cb0d80f4138f41201731a7fab4ba03f78d18236e85ba",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740386043,
      "headline": "European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention",
      "id": 132863358,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –– Both Applications Will Be Assessed in...",
      "url": "https://finnhub.io/api/news?id=aacf2aeb8946b8845ed4cb0d80f4138f41201731a7fab4ba03f78d18236e85ba"
    }
  }
]